Mapatumumab (agonistic human monoclonal antibody to TRAIL receptor-1): Review of in vitro and in vivo anti-lymphoma activity
Czuczman MS1 Hernandez-Ilizaliturri FJ,1 Vose J,2 Zelenetz AD,3 Smith MR,4 Burris H,5 Ansell S,6 Klein J,7 Kumm E,7 Gallant G,7 Younes A8
1Medicine, Roswell Park Cancer Institute, Buffalo, NY; 2Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE; 3Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York City, NY; 4Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA; 5Oncology, The Sarah Cannon Research Institute, Nashville, TN;
6Hematology, Mayo Clinic College of Medicine, Rochester, MN;
7Clinical Research/Biostatistics, Human Genome Sciences, Inc, Rockville, MD;
8Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX